

Amphotericin B Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel (Direct, Indirect), By End Use (Systemic Fungal Infections, Candidiasis, Aspergillosis, Mucormycosis, Leishmaniasis, Others), By Region and Competition, 2020-2030F

<https://marketpublishers.com/r/A7B61930FC30EN.html>

Date: April 2025

Pages: 185

Price: US\$ 4,500.00 (Single User License)

ID: A7B61930FC30EN

Abstracts

Global Amphotericin B market was valued at USD 69.41 million in 2024 and is projected to reach USD 105.54 million by 2030, growing at a compound annual growth rate (CAGR) of 2.91% during the forecast period. The market is experiencing consistent growth, primarily driven by the rising incidence of life-threatening fungal infections and the expanding population of immunocompromised individuals worldwide. Amphotericin B, a polyene antifungal agent, remains one of the most effective treatments for severe systemic mycoses, including cryptococcal meningitis, aspergillosis, mucormycosis, and candidiasis. Despite the emergence of newer antifungal agents, Amphotericin B continues to maintain significant therapeutic relevance, especially in hospital settings and in cases of multidrug resistance. A key factor contributing to the market's growth is the increasing prevalence of opportunistic fungal infections among immunocompromised patients, such as those undergoing chemotherapy, organ transplants, or living with HIV/AIDS. The rise in mucormycosis cases, particularly during the COVID-19 pandemic in certain regions, has further heightened the demand for Amphotericin B. Moreover, advancements in liposomal and lipid complex formulations have improved drug tolerability and reduced nephrotoxicity, further enhancing clinical adoption. Expanding healthcare access and growing awareness in developing economies are also driving greater use of antifungal therapies, thereby enhancing market potential.

Key Market Drivers

Growth in Healthcare Industry:

The continued expansion of the global healthcare sector is a major driver of the Amphotericin B market. The global hospital market is expected to generate USD 4.41 trillion in revenue by 2025. In the United States, hospitals are making significant investments in telemedicine to extend remote healthcare services, particularly in rural areas. As healthcare systems evolve and infrastructure improves in both developed and emerging economies, there is a growing emphasis on effective treatments for life-threatening fungal infections, where Amphotericin B remains a gold standard. Known for its potent antifungal properties, Amphotericin B is widely used in managing systemic mycoses, particularly in immunocompromised patients such as those with HIV/AIDS, cancer, or undergoing organ transplants.

Key Market Challenges

Toxicity and Adverse Side Effects:

A significant challenge facing the global Amphotericin B market is the drug's known toxicity and adverse side effects. Although Amphotericin B is considered a gold standard for treating severe fungal infections, its use is often limited by safety concerns, particularly nephrotoxicity, which can lead to acute kidney injury in a significant proportion of patients. Other common adverse effects include infusion-related reactions such as fever, chills, hypotension, and electrolyte imbalances. These side effects require intensive monitoring and hospitalization, thus increasing treatment costs and complexity. While liposomal and lipid-based formulations have helped mitigate some of these toxicities, their high cost limits broader adoption, particularly in resource-limited settings. The ongoing challenge of balancing efficacy with safety remains a major concern for healthcare providers and pharmaceutical manufacturers, highlighting the need for safer, equally effective alternatives or improved formulations in the antifungal therapeutics market.

Key Market Trends

Increasing Prevalence of Fungal Infections:

The rising global incidence of fungal infections has become a defining trend in the growth of the Amphotericin B market. It is estimated that invasive fungal infections occur

at a rate of approximately 6.5 million cases annually, leading to around 3.8 million deaths. Of these, an estimated 2.5 million fatalities—representing 68% (ranging between 35% and 90%)—are directly caused by these infections. Invasive aspergillosis alone affects over 2.1 million individuals annually, primarily among patients with chronic obstructive pulmonary disease (COPD), those in intensive care units, and individuals with hematologic malignancies or lung cancer. This condition has a concerning mortality rate of 85.2%. With the growing number of individuals affected by opportunistic and invasive fungal diseases, the demand for potent antifungal therapies such as Amphotericin B has significantly increased.

Key Market Players

Xiamen Neore Pharmaceutical Technology Co., Ltd

Concord Biotech Limited

United Biotech Pvt Ltd

Hubei Aoks Bio-Tech Co.,Ltd

Synbiotics Limited

North China Pharmaceutical Huasheng Co., Ltd

Xi'an Sonwu Biotech Co., Ltd.

Century Pharmaceutical Ltd

Xellia Pharmaceuticals

Report Scope

In this report, the Global Amphotericin B Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Amphotericin B Market, By Sales Channel:

Direct

Indirect

Amphotericin B Market, By End Use:

Systemic Fungal Infections

Candidiasis

Aspergillosis

Mucormycosis

Leishmaniasis

Others

Amphotericin B Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Amphotericin B Market.

Available Customizations:

Global Amphotericin B Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Amphotericin B Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Cha...

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, and Trends

4. IMPACT OF COVID-19 ON GLOBAL AMPHOTERICIN B MARKET

5. GLOBAL AMPHOTERICIN B MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Sales Channel (Direct, Indirect)
 - 5.2.2. By End Use (Systemic Fungal Infections, Candidiasis, Aspergillosis, Mucormycosis, Leishmaniasis, Others)
 - 5.2.3. By Region

- 5.2.4. By Company (2024)
- 5.3. Market Map

6. NORTH AMERICA AMPHOTERICIN B MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Sales Channel
 - 6.2.2. By End Use
 - 6.2.3. By Country
- 6.3. North America: Country Analysis
 - 6.3.1. United States Amphotericin B Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Sales Channel
 - 6.3.1.2.2. By End Use
 - 6.3.2. Mexico Amphotericin B Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Sales Channel
 - 6.3.2.2.2. By End Use
 - 6.3.3. Canada Amphotericin B Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Sales Channel
 - 6.3.3.2.2. By End Use

7. EUROPE AMPHOTERICIN B MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Sales Channel
 - 7.2.2. By End Use
 - 7.2.3. By Country

7.3. Europe: Country Analysis

7.3.1. France Amphotericin B Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Sales Channel

7.3.1.2.2. By End Use

7.3.2. Germany Amphotericin B Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Sales Channel

7.3.2.2.2. By End Use

7.3.3. United Kingdom Amphotericin B Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Sales Channel

7.3.3.2.2. By End Use

7.3.4. Italy Amphotericin B Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Sales Channel

7.3.4.2.2. By End Use

7.3.5. Spain Amphotericin B Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Sales Channel

7.3.5.2.2. By End Use

8. ASIA PACIFIC AMPHOTERICIN B MARKET OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Sales Channel

8.2.2. By End Use

8.2.3. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Amphotericin B Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Sales Channel

8.3.1.2.2. By End Use

8.3.2. India Amphotericin B Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Sales Channel

8.3.2.2.2. By End Use

8.3.3. South Korea Amphotericin B Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Sales Channel

8.3.3.2.2. By End Use

8.3.4. Japan Amphotericin B Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Sales Channel

8.3.4.2.2. By End Use

8.3.5. Australia Amphotericin B Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Sales Channel

8.3.5.2.2. By End Use

9. SOUTH AMERICA AMPHOTERICIN B MARKET OUTLOOK

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Sales Channel

- 9.2.2. By End Use
- 9.2.3. By Country
- 9.3. South America: Country Analysis
 - 9.3.1. Brazil Amphotericin B Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Sales Channel
 - 9.3.1.2.2. By End Use
 - 9.3.2. Argentina Amphotericin B Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Sales Channel
 - 9.3.2.2.2. By End Use
 - 9.3.3. Colombia Amphotericin B Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Sales Channel
 - 9.3.3.2.2. By End Use

10. MIDDLE EAST AND AFRICA AMPHOTERICIN B MARKET OUTLOOK

- 10.1. Market Size & Forecast
 - 10.1.1. By Value
- 10.2. Market Share & Forecast
 - 10.2.1. By Sales Channel
 - 10.2.2. By End Use
 - 10.2.3. By Country
- 10.3. MEA: Country Analysis
 - 10.3.1. South Africa Amphotericin B Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Sales Channel
 - 10.3.1.2.2. By End Use
 - 10.3.2. Saudi Arabia Amphotericin B Market Outlook
 - 10.3.2.1. Market Size & Forecast

- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Sales Channel
 - 10.3.2.2.2. By End Use
- 10.3.3. UAE Amphotericin B Market Outlook
 - 10.3.3.1. Market Size & Forecast
 - 10.3.3.1.1. By Value
 - 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Sales Channel
 - 10.3.3.2.2. By End Use

11. MARKET DYNAMICS

- 11.1. Drivers
- 11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments

13. GLOBAL AMPHOTERICIN B MARKET: SWOT ANALYSIS

14. PORTERS FIVE FORCES ANALYSIS

- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

- 15.1. Xiamen Neore Pharmaceutical Technology Co., Ltd
 - 15.1.1. Business Overview
 - 15.1.2. Company Snapshot
 - 15.1.3. Products & Services
 - 15.1.4. Financials (As Reported)

- 15.1.5. Recent Developments
- 15.1.6. Key Personnel Details
- 15.1.7. SWOT Analysis
- 15.2. Concord Biotech Limited
- 15.3. United Biotech Pvt Ltd
- 15.4. Hubei Aoks Bio-Tech Co.,Ltd
- 15.5. Synbiotics Limited
- 15.6. North China Pharmaceutical Huasheng Co., Ltd
- 15.7. Xi'an Sonwu Biotech Co., Ltd.
- 15.8. Century Pharmaceutical Ltd
- 15.9. Xellia Pharmaceuticals

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER

I would like to order

Product name: Amphotericin B Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel (Direct, Indirect), By End Use (Systemic Fungal Infections, Candidiasis, Aspergillosis, Mucormycosis, Leishmaniasis, Others), By Region and Competition, 2020-2030F

Product link: <https://marketpublishers.com/r/A7B61930FC30EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A7B61930FC30EN.html>